6 Jan 2016 07:00
6 January 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Group")
Notice of Results
Redx, the drug discovery and development company, will announce its results for the year ended 30 September 2015 on Wednesday 20 January 2016.
For further information, please contact:
Redx Pharma Plc | T: 0151 706 4747 |
Neil Murray, Chief Executive Company website: redxpharma.com | |
Shore Capital (Nomad and Broker) | T: 020 7408 4090 |
Bidhi Bhoma/ Edward Mansfield/ Patrick Castle | |
KTZ Communications | T: 020 3178 6378 |
Katie Tzouliadis |
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.